Population PK Analyses of Ubrogepant (MK‐1602), a CGRP Receptor Antagonist: Enriching In‐Clinic Plasma PK Sampling With Outpatient Dried Blood Spot Sampling-Reference-Cited by-同舟云学术

Population PK Analyses of Ubrogepant (MK‐1602), a CGRP Receptor Antagonist: Enriching In‐Clinic Plasma PK Sampling With Outpatient Dried Blood Spot Sampling

Published:2017-11-14 Issue:3 Volume:58 Page:294-303
ISSN:0091-2700
Container-title:The Journal of Clinical Pharmacology
language:en
Short-container-title:The Journal of Clinical Pharmacology

Author:

Li Chi‐Chung¹²,Dockendorf Marissa¹,Kowalski Ken³⁴,Yang Bei³,Xu Yang¹,Xie Iris¹,Kleijn Huub Jan¹⁵,Bosch Rolien¹⁶,Jones Christopher⁷,Thornton Bob⁷,Marcantonio Eugene E.⁸⁹,Voss Tiffini⁸,Bateman Kevin P.¹,Kothare Prajakti A.¹

Affiliation:

1. PharmacokineticsPharmacodynamicsand Drug MetabolismMerck & Co.Inc. Kenilworth NJ USA

2. Present affiliation: Clinical PharmacologyGenentechInc. South San Francisco CA USA

3. Ann Arbor Pharmacometrics Group Ann Arbor MI USA

4. Present affiliation: Kowalski PMetrics ConsultingLLC Northville MI USA

5. Present affiliation: CertaraInc.Oss The Netherlands

6. Present affiliation: Leiden Experts on Advanced Pharmacokinetics & Pharmacodynamics Leiden The Netherlands

7. Clinical ResearchMerck & Co.Inc. Kenilworth NJ USA

8. Translational PharmacologyMerck & Co.Inc. Kenilworth NJ USA

9. Present affiliation: ARMGO PharmaInc Tarrytown NY USA

Funder

Merck

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/jcph.1021

Reference8 articles.

1. An integrated strategy for implementation of dried blood spots in clinical development programs.;Kothare PA;AAPS J,2016

2. Clinical applications of new therapeutic deliveries in migraine

3. Why Triptan Treatment Can Fail: Focus on Gastrointestinal Manifestations of Migraine

4. Migraine associated with gastrointestinal disorders: review of the literature and clinical implications;Hemert S;Front Neurol,2014

5. Merck’s perspective on the implementation of dried blood spot technology in clinical drug development – why, when and how

Cited by 34 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Broadly Implementing “At‐Home Sampling” in Clinical Trials: What's Holding Us Back?;Clinical Pharmacology & Therapeutics;2023-12-15

2. A Comprehensive Review of the Mechanism, Efficacy, Safety, and Tolerability of Ubrogepant in the Treatment of Migraine;Cureus;2023-11-02

3. Validation of low-volume sampling devices for pharmacokinetic analysis: technical and logistical challenges and solutions;Bioanalysis;2023-10-19

4. Enabling Patient Centric Sampling Through Partnership;Patient Centric Blood Sampling and Quantitative Bioanalysis;2023-10-13

5. Is this the end of dried blood spots as we know it?;Analytical Science Advances;2023-07-19